SU 6668 (SU6668)

Subscribe to Selected New Research on SU 6668

39 relevant articles (6 outcomes, 8 trials/studies) found for this Bio-Agent

Description: structure in first source

Also Known As:

SU6668; (Z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid; (Z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid; SU006668

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Pyrroles: 12

SU 6668: 39

2-Ring Heterocyclic Compounds

Indoles: 69

SU 6668: 39

Experts

1.	Kubota, Tetsuro: 3 articles (01/2006 - 01/2005)
2.	Kitajima, Masaki: 3 articles (01/2006 - 01/2005)
3.	Huber, Peter E: 2 articles (01/2007 - 07/2003)
4.	Abdollahi, Amir: 2 articles (01/2007 - 07/2003)
5.	Ozawa, Soji: 2 articles (01/2006 - 09/2005)
6.	Abbruzzese, James L: 2 articles (01/2005 - 11/2004)
7.	Xiong, Henry Q: 2 articles (01/2005 - 11/2004)
8.	Cherrington, Julie M: 2 articles (08/2003 - 05/2002)
9.	Laird, A Douglas: 2 articles (10/2002 - 05/2002)
10.	Chu, Zhao-Hui: 1 article (07/2008)

Related Diseases

1.	Neoplasms (Cancer) 03/15/2002 - "We conclude that SU6668 is a potent therapeutic agent potentially useful to suppress tumor growth and enhance the response of tumors to radiotherapy." 11/01/2004 - "PURPOSE: To evaluate the biologic effects of SU6668 in patients with solid tumors using comprehensive measures of pharmacokinetics (PK), functional imaging, and tissue correlative studies" 01/01/2006 - "Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells." 03/20/2005 - "inoculation of tumor cells, SU6668 was orally administered 6 times weekly at a daily dose of 100 mg/kg or 400 mg/kg. The SU6668-administered group and the vehicle-administered control group were compared for the number of tumor vascular endothelial cells, weight of peritoneally disseminated tumors, amount of ascitic fluid and survival time" 02/01/2005 - "The animals were treated with intraperitoneal injections of SU6668 (75 mg/kg/day) immediately (five animals) or 7 days (five animals) following tumor implantation" Get all the results and reference details, order at left...
2.	Carcinoma (Carcinomatosis) 01/15/2004 - "In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model." 08/15/2003 - "CONCLUSIONS: This study shows that SU6668 in combination with paclitaxel inhibits ovarian carcinoma progression in the peritoneal cavity, by blocking ascites formation and tumor spread" 12/01/2005 - "Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models." 12/01/2005 - "SU5416 and SU6668) would be more effective in controlling tumor recurrence in a mouse model of human CNE2 poorly differentiated nasopharyngeal carcinoma compared with PDT or antiangiogenic agents administered alone" 08/15/2003 - "The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically." Get all the results and reference details, order at left...
3.	Glioma (Gliomas) 08/01/2000 - "Furthermore, intravital multifluorescence videomicroscopy of C6 glioma xenografts in the dorsal skinfold chamber model revealed that SU6668 treatment suppressed tumor angiogenesis" 02/01/2005 - "To assess the effects of SU6668 on overall survival, C6 glioma cells were implanted stereotactically into the brains of 24 additional animals and treatment was initiated on Day 7. In both the immediate and delayed experimental setting, SU6668 treatment resulted in a significant reduction of total and functional tumor vessel densities (both p < 0.05), reflecting a suppression of angiogenesis and impairment of tumor perfusion" 08/01/2000 - "administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin" 02/01/2005 - "OBJECT: The goal of this study was to determine the effects of SU6668, a polyvalent receptor tyrosine kinase inhibitor against vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor-beta, and fibroblast growth factor-1 on tumor growth, angiogenesis, and microcirculation in an orthotopic malignant glioma model" Get all the results and reference details, order at left...
4.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/01/2006 - "We treated xenografted A-431, a human squamous cell carcinoma cell line, with SU6668 to investigate the efficacy of tumor dormant therapy using angiogenesis inhibitors for patients with squamous cell carcinoma" Get all the results and reference details, order at left...
5.	Breast Neoplasms (Breast Cancer) 10/15/2002 - "The therapeutic efficacy of combined antiangiogenic and immune therapy was tested against weakly immunogenic and highly metastatic 4T1 breast tumor using SU6668, an angiogenesis inhibitor and recombinant murine (rm) B7.2-IgG fusion protein, an immunostimulator" 10/15/2002 - "Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein." Get all the results and reference details, order at left...
22 Diseases and 39 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	SU 5416 (SU5416)
2.	Angiogenesis Inhibitors
3.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
4.	glucuronyl glucosamine glycan sulfate (Vessel)
5.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
6.	1-phenyl-3,3-dimethyltriazene (PDT)
7.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
8.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
9.	Phosphotransferases (Kinase)
10.	Protein-Tyrosine Kinases (Tyrosine Kinase)
172 Drugs and Important Bio-Agents and 35 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Stents
3.	Photochemotherapy (Photodynamic Therapy)
3 Therapies and Procedures and 10 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>